Skip to main content
SpringerLink
Log in

Anticoagulant Therapies

  • Chapter
Management of Acute Coronary Syndromes

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 144 Accesses

Abstract

The underlying precipitant of unstable angina non-ST-segment elevation myocardial infarction (UA/NSTEMI) is the ruptured or fissured coronary plaque, or endothelial erosion, which elicits a complex interaction between the coagulation cascade and platelets to form a thrombus. The majority of these disruptions and resulting thrombi cause only insignificant obstruction to coronary blood flow. However, a large thrombus can cause a significant impediment to coronary flow resulting in ischemia. This thrombus may resolve spontaneously with restoration of blood flow, or propagate to cause further ischemia. Often, this process can lead to complete occlusion of the vessel precipitating a myocardial infarction (MI) (1–9).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fuster V, Badimon L, Cohen M, Ambrose J, Badimon J, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213–1220.

    Article  PubMed  CAS  Google Scholar 

  2. Fuster V, Stein B, Ambrose J, Badimon L, Badimon J, Chesebro J. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990;82(Suppl. II):II-47-II-59.

    Google Scholar 

  3. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126–2146.

    Article  PubMed  CAS  Google Scholar 

  4. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–670.

    Article  PubMed  CAS  Google Scholar 

  5. Stein B, Fuster V, Halperin J, Chesebro J. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989; 80: 1502–1513.

    Google Scholar 

  6. Theroux P, Lidon R. Unstable angina: pathogenesis, diagnosis, and treatment. Curr Probl Cardiol 1993; 18: 157–231.

    Article  PubMed  CAS  Google Scholar 

  7. Cairns J, Lewis D Jr, Meade T, Sutton G, Theroux P. Antithrombotic agents in coronary artery disease. Chest 1995; 108 (Suppl.): 380S - 400S.

    Article  PubMed  CAS  Google Scholar 

  8. Grambow D, Topol E. Effect of maximal medical therapy on refractoriness of unstable angina pectoris. Am J Cardiol 1992; 70: 577–581.

    Article  PubMed  CAS  Google Scholar 

  9. DeWood M, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897–902.

    Article  PubMed  CAS  Google Scholar 

  10. Lewis H, Davis J, Archibald D, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403.

    Article  PubMed  Google Scholar 

  11. Cairns J, Gent M, Singer J, et al. Aspirin, sulfinpyrazone or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–1375.

    Article  PubMed  CAS  Google Scholar 

  12. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830.

    Article  Google Scholar 

  13. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled, multicenter clinical trial. Circulation 1990; 82: 17–26.

    Article  PubMed  CAS  Google Scholar 

  14. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.

    Article  Google Scholar 

  15. Oler A, Whooley M, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811–815.

    Article  PubMed  CAS  Google Scholar 

  16. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936–1942.

    Article  PubMed  CAS  Google Scholar 

  17. Cohen M, Antman EM, Murphey SA, Radley D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. Am Heart J 2002; 143: 63–69.

    Article  PubMed  Google Scholar 

  18. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565–1574.

    Article  PubMed  CAS  Google Scholar 

  19. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988; 260: 2088–2093.

    Article  PubMed  CAS  Google Scholar 

  20. Hennekens D, O’Donnell C, Ridker P. Current and future perspectives on antithrombotic therapy of acute myocardial infarction. Eur Heart J 1995; 16 (Suppl. D): 2–9.

    PubMed  CAS  Google Scholar 

  21. Telford A, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1: 1225–1228.

    Article  PubMed  CAS  Google Scholar 

  22. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–1111.

    Article  PubMed  CAS  Google Scholar 

  23. Theroux P, Waters D, Qui S, McCans J, deGuise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045–2048.

    Article  PubMed  CAS  Google Scholar 

  24. Neri Serneri G, Gensini G, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 1990; 335: 615–618.

    Article  PubMed  CAS  Google Scholar 

  25. Neri Serneri GG, Modesti PA, Gensini GG, et al. Randomized comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell’Angina Insto-bile (SESAIR) Refrattorie Group. Lancet 1995; 345: 1201–1204.

    Article  PubMed  CAS  Google Scholar 

  26. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141–145.

    Article  PubMed  CAS  Google Scholar 

  27. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic therapy in acute coronary syndromes research group. Circulation 1994; 89: 81–88.

    Article  PubMed  CAS  Google Scholar 

  28. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39–45.

    Article  PubMed  CAS  Google Scholar 

  29. Menon V, Berkowitz SD, Antman EM, Fuchs RM, Hochman JS New heparin dosing recommendations for patients with acute coronary syndromes. Am J Med 2001; 110: 641–650.

    Article  PubMed  CAS  Google Scholar 

  30. Cohen M, Blaber R. Potential uses of a new class of low-molecular weight heparins in cardiovascular indications. Thromb Haemost 1996; 22 (Suppl. 2): 25–27.

    Google Scholar 

  31. Samama M, Bara L, Gerotziafas G. Mechanisms for the antithrombotic activity in man of low molecular weight heparins. Haemostasis 1994; 24: 105–117.

    PubMed  CAS  Google Scholar 

  32. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688–698.

    Article  PubMed  CAS  Google Scholar 

  33. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–1335.

    Article  PubMed  CAS  Google Scholar 

  34. Planes A, Vochelle N, Mazzas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407–410.

    PubMed  CAS  Google Scholar 

  35. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975–982.

    Article  PubMed  CAS  Google Scholar 

  36. Lensing A, Prins M, Davidson B, Hirsh J. treatment of deep venous thrombosis with low molecular weight heparins: a meta-analysis. Arch Intern Med 1995; 155: 601–607.

    CAS  Google Scholar 

  37. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996: 334: 677–681.

    Article  PubMed  CAS  Google Scholar 

  38. Koopman M, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996; 334: 682–687.

    Article  PubMed  CAS  Google Scholar 

  39. Leizorovicz A, Simoneau G, Decousus H, Boissel J. Comparison of efficacy and safety of low molecular weight heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299–304.

    Article  CAS  Google Scholar 

  40. Edmondson R, Cohen A, Das S, Wagner M, Kakkar V. Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994; 344: 914–918.

    Article  PubMed  CAS  Google Scholar 

  41. Kay R, Wong D, Yu Y, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588–1593.

    Article  PubMed  CAS  Google Scholar 

  42. Gurfinkel E, Manos E, Mejail R, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313–318.

    Article  PubMed  CAS  Google Scholar 

  43. Wallentin L, for the Fragmin During Instability in Coronary Artery Disease (FRISC) Group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561–568.

    Google Scholar 

  44. Klein W, Buchwald A, Hillis S, et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61–68.

    Article  PubMed  CAS  Google Scholar 

  45. Fragmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Long-term low molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701–707.

    Article  Google Scholar 

  46. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452.

    Article  PubMed  CAS  Google Scholar 

  47. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000; 36: 693–698.

    Article  PubMed  CAS  Google Scholar 

  48. Montalescot G, Collet JP, Choussat R, Ankri A, Thomas D. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. Int J Cardiol 2000; 72: 293–294.

    Article  PubMed  CAS  Google Scholar 

  49. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110–114.

    Article  PubMed  CAS  Google Scholar 

  50. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol 1997;29:1474–1482.

    Google Scholar 

  51. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–1601.

    Article  PubMed  CAS  Google Scholar 

  52. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602–1608.

    Article  PubMed  CAS  Google Scholar 

  53. Antman EM, Cohen M, McCabe C, et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year followup of TIMI 11B and ESSENCE. Eur Heart J 2002; 23: 308–314.

    Article  PubMed  CAS  Google Scholar 

  54. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin wiht a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553–1562.

    Google Scholar 

  55. Michalis LK, Papamichail N, Katsouras CS, et al. Enoxaparin Versus Tinzaparin in the Management of Unstable Coronary Artery Disease (EVET Study) J Am Coll Cardiol 2001; 37 (Suppl. A): 365A.

    Google Scholar 

  56. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273–281.

    Article  PubMed  CAS  Google Scholar 

  57. Cohen M, et al. Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation 2000; 102: II - 826.

    Article  Google Scholar 

  58. Ferguson JJ, et al. The use of enoxaparin and IIb /IIIa antagonists in acute coronary syndromes-final results of the NICE-3 study. J Am Coll Cardiol 2001: 37: 365A.

    Google Scholar 

  59. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–1924.

    Article  Google Scholar 

  60. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13: 272–278.

    PubMed  CAS  Google Scholar 

  61. Bhatt L, Lincoff AM, The CRUISE Investigators. Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: the results of the CRUISE trial [abstract]. Circulation 2001; 104: 11–384.

    Google Scholar 

  62. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001; 103: 658–663.

    Article  PubMed  CAS  Google Scholar 

  63. Cohen M. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction. Semin Thromb Hemost 1999; 25 (Suppl. 3): 113–121.

    PubMed  CAS  Google Scholar 

  64. Montalescot G, Drouet L. ARMADA study: a randomized comparison of enoxaparin, dalteparin and unfractionated heparin on markers of cell activation in patients with unstable angina Eur Heart J 2001; 22; 663.

    Google Scholar 

  65. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36 (1): 110–114.

    Article  PubMed  CAS  Google Scholar 

  66. Lidon R, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina. anticoagulant, antithrombotic, and clinical effects. Circulation 1993; 88: 1495–1501.

    Article  PubMed  CAS  Google Scholar 

  67. Cannon C, Braunwald E. Hirudin: intial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol 1995; 25 (Suppl. 7): 30S - 37S.

    Article  PubMed  CAS  Google Scholar 

  68. Heras M, Chesebro J, Webster M, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476–1484.

    Article  PubMed  CAS  Google Scholar 

  69. Cannon C, McCabe C, Henry T, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of TIMI 5 trial. J Am Coll Cardiol 1994; 23: 993–1003.

    Article  PubMed  CAS  Google Scholar 

  70. Topol E, Fuster V, Harrington R, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation 1994; 89: 1557–1566.

    Article  PubMed  CAS  Google Scholar 

  71. Fuchs J, Cannon C. Hirulog in the treatment of unstable angina. Results of the TIMI 7 trial. Circulation 1995; 92: 727–733.

    Article  PubMed  CAS  Google Scholar 

  72. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 33: 775–782.

    Google Scholar 

  73. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997; 96: 769–777.

    Article  Google Scholar 

  74. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353: 429–438.

    Article  Google Scholar 

  75. Kong D, Topol E, Bittl J, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999; 100: 2049–2053.

    Article  PubMed  CAS  Google Scholar 

  76. White HD. The HERO-2 trial. Presented at the European Society of Cardiology-XXIII Congress, 2001.

    Google Scholar 

  77. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Eur Heart J 1997; 18 (9): 1416–1425.

    Article  Google Scholar 

  78. McClanahan T, Hicks G, Ignasiak D, et al. The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis. J Thromb Thrombolysis 2000; 10: 277–284.

    Article  PubMed  CAS  Google Scholar 

  79. Van Aken H, Bode C, Darius H, et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost 2001; 7: 195–204.

    Article  PubMed  Google Scholar 

  80. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral pro-drug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171–181.

    Article  PubMed  CAS  Google Scholar 

  81. Mikulski A, Elg M, Gustafsson D. The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thromb Res 2001; 101: 477–482.

    Article  PubMed  CAS  Google Scholar 

  82. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of longterm, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001; 37: 475–484.

    Article  Google Scholar 

  83. Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 3069–3074.

    Article  PubMed  CAS  Google Scholar 

  84. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation 1994; 89: 81–88.

    Article  PubMed  CAS  Google Scholar 

  85. Hurlen M, Smith P, Abdelnorr M, Erikssen J, Arnesen H. Effects of warfarin, aspirin and the two combined on mortality and thrombo-embolic morbidity after myocardial infarction. Presented at the 23rd Annual Meeting of the European Society of Cardiology, 2001.

    Google Scholar 

Download references

Authors
  1. Marc Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

    Christopher P. Cannon MD (Associate Professor of Medicine) (Associate Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Cohen, M. (2003). Anticoagulant Therapies. In: Cannon, C.P. (eds) Management of Acute Coronary Syndromes. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-351-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-351-4_16

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-58829-309-1

  • Online ISBN: 978-1-59259-351-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation